| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Leon French, Courtney Gray, Gabriel Leonard, Michel Perron, G Bruce Pike, Louis Richer, Jean R Séguin, Suzanne Veillette, C John Evans, Eric Artiges, Tobias Banaschewski, Arun W L Bokde, Uli Bromberg, Ruediger Bruehl, Christian Buchel, Anna Cattrell, Patricia J Conrod, Herta Flor, Vincent Frouin, Jurgen Gallinat, Hugh Garavan, Penny Gowland, Andreas Heinz, Herve Lemaitre, Jean-Luc Martinot, Frauke Nees, Dimitri Papadopoulos Orfanos, Melissa Marie Pangelinan, Luise Poustka, Marcella Rietschel, Michael N Smolka, Henrik Walter, Robert Whelan, Nic J Timpson, Gunter Schumann, George Davey Smith, Zdenka Pausova, Tomáš Pau. Early Cannabis Use, Polygenic Risk Score for Schizophrenia and Brain Maturation in Adolescence. JAMA psychiatry. vol 72. issue 10. 2016-01-12. PMID:26308966. |
cannabis use during adolescence is known to increase the risk for schizophrenia in men. |
2016-01-12 |
2023-08-13 |
Not clear |
| Katherine A Epstein, Sanjiv Kumr. Altered cortical maturation in adolescent cannabis users with and without schizophrenia. Schizophrenia research. vol 162. issue 1-3. 2016-01-04. PMID:25600549. |
altered cortical maturation in adolescent cannabis users with and without schizophrenia. |
2016-01-04 |
2023-08-13 |
human |
| Katherine A Epstein, Sanjiv Kumr. Altered cortical maturation in adolescent cannabis users with and without schizophrenia. Schizophrenia research. vol 162. issue 1-3. 2016-01-04. PMID:25600549. |
however, the impact of cannabis use disorder (cud) upon cortical gray matter development in both healthy adolescents and adolescents with early-onset schizophrenia (eos) is unclear. |
2016-01-04 |
2023-08-13 |
human |
| Tabitha A Iseger, Matthijs G Bosson. A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophrenia research. vol 162. issue 1-3. 2016-01-04. PMID:25667194. |
however, the non-psychotropic, plant-derived cannabinoid agent cannabidiol (cbd) may have antipsychotic properties, and thus may be a promising new agent in the treatment of schizophrenia. |
2016-01-04 |
2023-08-13 |
human |
| Bernard A Fischer, Robert P McMahon, Deanna L Kelly, Heidi J Wehring, Walter A Meyer, Stephanie Feldman, William T Carpenter, David A Gorelic. Risk-taking in schizophrenia and controls with and without cannabis dependence. Schizophrenia research. vol 161. issue 2-3. 2015-12-31. PMID:25467541. |
risk-taking in schizophrenia and controls with and without cannabis dependence. |
2015-12-31 |
2023-08-13 |
Not clear |
| Bernard A Fischer, Robert P McMahon, Deanna L Kelly, Heidi J Wehring, Walter A Meyer, Stephanie Feldman, William T Carpenter, David A Gorelic. Risk-taking in schizophrenia and controls with and without cannabis dependence. Schizophrenia research. vol 161. issue 2-3. 2015-12-31. PMID:25467541. |
risk-based decision making is altered in people with schizophrenia and in people with cannabis use compared to healthy controls; the pattern of risk-assessment in people with co-occurring schizophrenia and cannabis dependence is poorly understood. |
2015-12-31 |
2023-08-13 |
Not clear |
| Bernard A Fischer, Robert P McMahon, Deanna L Kelly, Heidi J Wehring, Walter A Meyer, Stephanie Feldman, William T Carpenter, David A Gorelic. Risk-taking in schizophrenia and controls with and without cannabis dependence. Schizophrenia research. vol 161. issue 2-3. 2015-12-31. PMID:25467541. |
this study examined measures of risk-taking and decision-making in people with and without schizophrenia and/or cannabis dependence. |
2015-12-31 |
2023-08-13 |
Not clear |
| Shaun M Eack, Susan S Hogarty, Deborah P Greenwald, Maralee Y Litschge, Summer A F McKnight, Srihari S Bangalore, Michael F Pogue-Geile, Matcheri S Keshavan, Jack R Corneliu. Cognitive Enhancement Therapy in substance misusing schizophrenia: results of an 18-month feasibility trial. Schizophrenia research. vol 161. issue 2-3. 2015-12-31. PMID:25510926. |
a total of 31 schizophrenia outpatients meeting addiction severity criteria for alcohol and/or cannabis use were randomized to 18months of cet or usual care. |
2015-12-31 |
2023-08-13 |
Not clear |
| Shaun M Eack, Susan S Hogarty, Deborah P Greenwald, Maralee Y Litschge, Summer A F McKnight, Srihari S Bangalore, Michael F Pogue-Geile, Matcheri S Keshavan, Jack R Corneliu. Cognitive Enhancement Therapy in substance misusing schizophrenia: results of an 18-month feasibility trial. Schizophrenia research. vol 161. issue 2-3. 2015-12-31. PMID:25510926. |
these results suggest that once engaged and stabilized, cet is a feasible and potentially effective treatment for cognitive impairments in patients with schizophrenia who misuse alcohol and/or cannabis. |
2015-12-31 |
2023-08-13 |
Not clear |
| Samuel Sarrazin, Florence Louppe, Raphael Doukhan, Franck Schürhof. A clinical comparison of schizophrenia with and without pre-onset cannabis use disorder: a retrospective cohort study using categorical and dimensional approaches. Annals of general psychiatry. vol 14. 2015-12-22. PMID:26692885. |
a clinical comparison of schizophrenia with and without pre-onset cannabis use disorder: a retrospective cohort study using categorical and dimensional approaches. |
2015-12-22 |
2023-08-13 |
human |
| Samuel Sarrazin, Florence Louppe, Raphael Doukhan, Franck Schürhof. A clinical comparison of schizophrenia with and without pre-onset cannabis use disorder: a retrospective cohort study using categorical and dimensional approaches. Annals of general psychiatry. vol 14. 2015-12-22. PMID:26692885. |
a high prevalence of cannabis use disorder has been reported in subjects suffering from schizophrenia, fuelling intense debate about whether schizophrenia with pre-onset cannabis use disorder may be a distinct entity with specific features or whether cannabis use disorder can precipitate schizophrenia in genetically vulnerable subjects. |
2015-12-22 |
2023-08-13 |
human |
| Timothy I Michaels, Vladan Novakovi. Can cannabis cause psychosis? Clinical neuropharmacology. vol 38. issue 2. 2015-11-30. PMID:25768856. |
to the extent that these changes in policy lead to increase widespread use, it is important to consider the association between heavy chronic cannabis use and the onset of psychotic illnesses, such as schizophrenia. |
2015-11-30 |
2023-08-13 |
Not clear |
| Vishal Bhavsa. Environmental factors, including cannabis, are strongly related to the age of onset and morbidity of schizophrenia. Evidence-based mental health. vol 18. issue 3. 2015-11-27. PMID:25979516. |
environmental factors, including cannabis, are strongly related to the age of onset and morbidity of schizophrenia. |
2015-11-27 |
2023-08-13 |
Not clear |
| Katherine A Epstein, Sanjiv Kumr. White matter fractional anisotropy over two time points in early onset schizophrenia and adolescent cannabis use disorder: A naturalistic diffusion tensor imaging study. Psychiatry research. vol 232. issue 1. 2015-11-20. PMID:25779033. |
white matter fractional anisotropy over two time points in early onset schizophrenia and adolescent cannabis use disorder: a naturalistic diffusion tensor imaging study. |
2015-11-20 |
2023-08-13 |
human |
| Isabel Morales-Muñoz, Rosa Jurado-Barba, Montserrat Caballero, Roberto Rodríguez-Jiménez, Miguel Ángel Jiménez-Arriero, Sara Fernández-Guinea, Gabriel Rubi. Cannabis abuse effects on prepulse inhibition in patients with first episode psychosis in schizophrenia. The Journal of neuropsychiatry and clinical neurosciences. vol 27. issue 1. 2015-11-13. PMID:25716487. |
cannabis abuse effects on prepulse inhibition in patients with first episode psychosis in schizophrenia. |
2015-11-13 |
2023-08-13 |
human |
| Isabel Morales-Muñoz, Rosa Jurado-Barba, Montserrat Caballero, Roberto Rodríguez-Jiménez, Miguel Ángel Jiménez-Arriero, Sara Fernández-Guinea, Gabriel Rubi. Cannabis abuse effects on prepulse inhibition in patients with first episode psychosis in schizophrenia. The Journal of neuropsychiatry and clinical neurosciences. vol 27. issue 1. 2015-11-13. PMID:25716487. |
deficits in prepulse inhibition (ppi) and cannabis abuse are consistently found in schizophrenia. |
2015-11-13 |
2023-08-13 |
human |
| Isabel Morales-Muñoz, Rosa Jurado-Barba, Montserrat Caballero, Roberto Rodríguez-Jiménez, Miguel Ángel Jiménez-Arriero, Sara Fernández-Guinea, Gabriel Rubi. Cannabis abuse effects on prepulse inhibition in patients with first episode psychosis in schizophrenia. The Journal of neuropsychiatry and clinical neurosciences. vol 27. issue 1. 2015-11-13. PMID:25716487. |
the authors studied ppi deficits in first episode psychosis (fep) with schizophrenia and cannabis abuse influence. |
2015-11-13 |
2023-08-13 |
human |
| b' Alexandra Gallo, Claude Bouchard, Emmanuel Fortier, Charles Ducrot, Pierre-Paul Rompr\\xc3\\xa. Cannabinoids reward sensitivity in a neurodevelopmental animal model of schizophrenia: a brain stimulation reward study. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 24. issue 9. 2015-11-02. PMID:25092427.' |
the comorbidity schizophrenia and cannabis has a high prevalence. |
2015-11-02 |
2023-08-13 |
rat |
| b' Alexandra Gallo, Claude Bouchard, Emmanuel Fortier, Charles Ducrot, Pierre-Paul Rompr\\xc3\\xa. Cannabinoids reward sensitivity in a neurodevelopmental animal model of schizophrenia: a brain stimulation reward study. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 24. issue 9. 2015-11-02. PMID:25092427.' |
the consumption of cannabis is ten times higher among schizophrenia patients, suggesting that these patients could be differentially sensitive to its motivational effects. |
2015-11-02 |
2023-08-13 |
rat |
| Matthew J Smith, Derin J Cobia, Lei Wang, Kathryn I Alpert, Will J Cronenwett, Morris B Goldman, Daniel Mamah, Deanna M Barch, Hans C Breiter, John G Csernansk. Cannabis-related working memory deficits and associated subcortical morphological differences in healthy individuals and schizophrenia subjects. Schizophrenia bulletin. vol 40. issue 2. 2015-10-23. PMID:24342821. |
we examined whether a cannabis use disorder (cud) was associated with differences in brain morphology between control subjects with and without a cud and between schizophrenia subjects with and without a cud, and whether these differences related to wm and cud history. |
2015-10-23 |
2023-08-12 |
human |